All In Biotech

Drug Trial Radar · NCT04934514

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

A Phase I/IIa Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

97

Planned (sponsor's estimate)

Start

Jul 6, 2021

Primary completion

Dec 31, 2024

Study completion Mar 31, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of IAH0968 in patients with HER2-positive advanced solid tumors who have failed standard treatment.

Conditions

  • Advanced Solid Tumor

Interventions

  • IAH0968Biological

    IAH0968 is an investigational product.

  • GemcitabineDrug

    Gemcitabine 1000 mg/m\^2 intravenous infusion

  • CisplatinDrug

    Cisplatin 75 mg/m\^2 intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events (AEs) and SAEs (Phase Ⅰ)Time frame: 3 months after end event visit
  2. Dose limiting toxicities (DLTs) (Phase Ⅰ)Time frame: 21 days after first dose
  3. Objective response rate (ORR) in dose expansion (Phase Ⅱa)Time frame: Baseline through up to 2 years or until disease progression

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.